Loading...
•
Dec 31, 2025
Ultragenyx Q4 2025 Earnings Report
Ultragenyx reported its financial results for the fourth quarter and full year ended December 31, 2025, showing a 25% increase in total revenue for the quarter compared to the same period in 2024.
Key Takeaways
Ultragenyx reported a strong fourth quarter in 2025 with total revenue reaching $207 million, a 25% increase year-over-year. The company also initiated a strategic restructuring plan to reduce expenses and headcount, aiming for profitability in 2027, and highlighted key clinical and regulatory catalysts for 2026.
Total revenue for Q4 2025 was $207 million, marking a 25% increase from Q4 2024.
Crysvita revenue for Q4 2025 was $145 million, with significant contributions from Latin America and Türkiye.
The company initiated a strategic restructuring plan to reduce operating expenses and headcount, targeting profitability by 2027.
Key catalysts for 2026 include potential approvals for DTX401 and UX111, and pivotal Phase 3 data from the GTX-102 Aspire study for Angelman syndrome.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Ultragenyx expects total revenue from current products in 2026 to be between $730 million and $760 million, representing an 8% to 13% increase compared to 2025. The company also anticipates significant reductions in R&D expenses by 2027 due to the completion of multiple Phase 3 studies and reduced early-stage research efforts.
Positive Outlook
- Total revenues for 2026 (excluding new product launches) are projected to increase by 8% to 13% compared to 2025, ranging from $730 million to $760 million.
- Crysvita revenue is expected to be between $500 million and $520 million in 2026, driven by growing global demand.
- Dojolvi revenue is projected to be between $100 million and $110 million in 2026.
- Combined R&D and SG&A expenses in 2026 are expected to be flat to down low-single digits versus 2025, despite including approximately $50 million for non-recurring restructuring charges.
- R&D expenses are expected to decrease by 38% (approximately $280 million) from 2025 levels by 2027, due to the completion of multiple Phase 3 studies and reduced early-stage research.
Challenges Ahead
- Crysvita revenue guidance for 2026 reflects growing underlying global demand partially offset by expected timing of ordering patterns in Brazil.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...